155 related articles for article (PubMed ID: 38219795)
1. Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lin G; Wang Z; Chu Q; Hu Y; Huang D; Wang J; Yang F; Zhong W; Zhou C; Zhu B; Ai X; Cao B; Cao Y; Chen M; Chen X; Chu T; Duan J; Fan Y; Fang Y; Feng S; Feng W; Guo H; Han C; He Y; Hong S; Hu J; Huang M; Huang Y; Jiang D; Jiang K; Jiang R; Jin B; Jin S; Li J; Li M; Li Z; Li C; Lin J; Liu A; Liu SM; Yutao L; Liu Z; Liu Z; Liu Z; Liu Z; Liu Z; Lu Y; Lv T; Ma Z; Miao Q; Peng M; Pu X; Ren XB; Shan J; Shan J; Shen P; Shen B; Shi M; Song Y; Song Z; Su C; Sun J; Tian P; Wang J; Wang F; Wang H; Wang J; Wang Q; Wang W; Wang Y; Wu L; Wu F; Xia Y; Xie C; Xie C; Xin T; Xiong J; Xu H; Xu S; Xu Y; Xu B; Xu C; Yan X; Yang Z; Yao W; Yu Y; Feng Y; Yu Z; Yu Y; Yue D; Zhang H; Zhang H; Zhang L; Zhang L; Zhang Q; Zhang T; Zhang B; Zhao J; Zhao M; Zheng X; Zhong Q; Zhou J; Zhou P; Zhu Z; Zou J; Zou Z
Thorac Cancer; 2024 Feb; 15(5):419-426. PubMed ID: 38219795
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
Xu Z; Hao X; Yang K; Wang Q; Wang J; Lin L; Teng F; Li J; Xing P
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3081-3089. PubMed ID: 34982222
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
Xu M; Hao Y; Shi Z; Song Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17987-17995. PubMed ID: 37975902
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.
Takahara Y; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Sakuma T; Nishiki K; Nakase K; Nojiri M; Kato R; Shinomiya S; Fujimoto Y; Oikawa T; Mizuno S
Thorac Cancer; 2022 Feb; 13(4):624-630. PubMed ID: 34989146
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse.
Livanou ME; Nikolaidou V; Skouras V; Fiste O; Kotteas E
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539530
[TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient.
Kagohashi K; Miyazaki K; Shiozawa T; Satoh H
Adv Respir Med; 2021; 89(3):316-319. PubMed ID: 34196384
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review.
Zhang H; Hu Y; Wu T; Chen Y; Yang B; Xie T
Front Immunol; 2023; 14():1309055. PubMed ID: 38283354
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
Gobbini E; Toffart AC; Pérol M; Assié JB; Duruisseaux M; Coupez D; Dubos C; Westeel V; Delaunay M; Guisier F; Veillon R; Gounant V; Giroux Leprieur E; Vanel FR; Chaabane N; Dansin E; Babey H; Decroisette C; Barlesi F; Daniel C; Fournel P; Mezquita L; Oulkhouir Y; Canellas A; Duchemann B; Molinier O; Alcazer V; Moro-Sibilot D; Levra MG
Clin Lung Cancer; 2020 Sep; 21(5):e497-e510. PubMed ID: 32605892
[TBL] [Abstract][Full Text] [Related]
13. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
[TBL] [Abstract][Full Text] [Related]
14. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qin Q; Wang J; Wang H
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
[TBL] [Abstract][Full Text] [Related]
15. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.
Feng Y; Tao Y; Chen H; Zhou Y; Tang L; Liu C; Hu X; Shi Y
Thorac Cancer; 2023 Sep; 14(25):2536-2547. PubMed ID: 37551891
[TBL] [Abstract][Full Text] [Related]
18. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
19. Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report.
Yao Y; Liu Z; Li Q; Cao B; Wang M
Thorac Cancer; 2022 Feb; 13(3):497-501. PubMed ID: 35014762
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
